Abstract:LBA2 Background: Gemcitabine-cisplatin (GP) chemotherapy is the standard 1 st line treatment for locally advanced, recurrent or metastatic (r/m) NPC. Toripalimab, a humanized IgG4K monoclonal antibody specific for PD-1, provided durable responses in patients (pts) with r/m NPC as monotherapy in the ≥2 nd line setting (POLARIS-02 study). The results of JUPITER-02, a randomized, placebo-controlled, double-blinded Phase III trial of toripalimab in combination with GP chemotherapy as first-line treatment for r/m NPC are summarized. Methods: Pts with advanced NPC with no prior chemotherapy in the r/m setting were randomized (1:1) to receive toripalimab 240 mg or placebo d1 in combination with gemcitabine 1000 mg/m 2 d1, d8 and cisplatin 80 mg/m 2 d1 every 3 weeks (Q3W) for up to 6 cycles, followed by monotherapy with toripalimab or placebo Q3W until disease progression, intolerable toxicity, or completion of 2 years of treatment. Stratification factors were ECOG PS (0 vs. 1) and extent of disease (recurrent vs. primary metastatic) at enrollment. Progression-free survival (PFS) and response were assessed by independent review committee (IRC) per RECIST v1.1. The primary endpoint was PFS by IRC in the ITT population. Secondary end points included ORR, DOR and OS. There was one prespecified interim analysis of PFS at 130 PFS events with a planned final analysis at 200 PFS events. Results: 289 pts were randomized: 146 to the toripalimab arm and 143 to the placebo arm. By May 30, 2020 as the interim analysis cutoff date, the median treatment duration was 39 weeks in the toripalimab arm and 36 weeks in the placebo arm. A significant improvement in PFS was detected for the toripalimab arm compared to the placebo arm (HR = 0.52 [95% CI: 0.36-0.74] two-sided p = 0.0003), with median PFS of 11.7 vs. 8.0 months. The 1-year PFS rates were 49% and 28% respectively. An improvement in PFS was observed across relevant subgroups, including all PD-L1 subgroups. The ORR was 77.4% vs. 66.4% (P = 0.033) and the median DOR was 10.0 vs. 5.7 months (HR = 0.50 [95% CI: 0.33-0.78]). As of Jan 15, 2021, OS was not mature, with 25 deaths in the toripalimab arm and 35 in the placebo arm (HR = 0.68 [95% CI: 0.41-1.14], P = 0.14). The incidence of Grade ≥3 adverse events (AEs) (89.0% vs 89.5%); AEs leading to discontinuation of toripalimab/placebo (7.5% vs 4.9%); and fatal AEs (2.7% vs 2.8%) were similar between two arms; however, immune-related (irAEs) (39.7% vs. 18.9%) and Grade ≥3 irAEs (7.5% vs. 0.7%) were more frequent in the toripalimab arm. Conclusions: The addition of toripalimab to GP chemotherapy as 1 st -line treatment for pts with advanced NPC provided superior PFS and ORR and longer DOR than GP alone with a manageable safety profile. These results support the use of toripalimab with GP chemotherapy as the new standard care for this population. Clinical trial information: NCT03581786.

1373MO JUPITER-06: A Randomized, Double-Blind, Phase III Study of Toripalimab Versus Placebo in Combination with First-Line Chemotherapy for Treatment Naive Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Clinical Response and Biomarker Analysis of a Phase II Basket Trial of Toripalimab, a PD-1 Mab in Combination with Standard Chemotherapy As a First-Line Treatment for Patients with Solid Tumors.

A Multi-Center Phase II Study of Toripalimab with Chemotherapy in Patients with EGFR Mutant Advanced NSCLC Patients Resistant to EGFR TKIs: Efficacy and Biomarker Analysis.

Cost-effectiveness of toripalimab plus chemotherapy for advanced esophageal squamous cell carcinoma

A Phase III, Randomized, Open-Label Study to Compare the Efficacy of Tislelizumab Versus Chemotherapy As Second-Line Therapy for Advanced Unresectable/metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Association of Frequent Amplification of Chromosome 11q13 in Esophageal Squamous Cell Cancer with Clinical Benefit to Immune Check Point Blockade.

Comparing toripalimab combined with chemoradiotherapy versus chemoradiotherapy alone for locally advanced esophageal squamous cell carcinoma: A multicenter, open-label, randomized phase II clinical trial.

Toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: a single-arm phase 2 trial

A Randomized Phase II/III Study of Paclitaxel/cisplatin Versus Cisplatin/5-Fluorouracil in Neoadjuvant Chemoradiotherapy (CRT) Followed by Surgery for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC).

A Single-Arm Phase II Study of Cabozantinib and Atezolizumab in Patients with Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (R/M ESCC) Who Failed Platinum-Based Chemotherapy.

Anti-PD1/PDL1 Antibodies Plus Chemotherapy As First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

A Phase III Trial in Progress Comparing Tislelizumab Plus Concurrent Chemoradiotherapy (ccrt) with Placebo Plus Ccrt in Patients with Localized Esophageal Squamous Cell Carcinoma (ESCC).

JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).

ORIENT-15: A randomized, multicenter, double-blind, Phase III study of sintilimab plus paclitaxel and cisplatin (TP) versus placebo plus TP as first-line treatment in patients with unresectable locally advanced or metastatic esophageal squamous cell carcinoma

TORIPALIMAB IN COMBINATION WITH CONCURRENT CHEMORADIATION IN PATIENTS WITH ADVANCED/METASTATIC ESOPHAGEAL CARCINOMA: PROTOCOL FOR A SINGLE-ARM, PROSPECTIVE, OPEN-LABEL, PHASE II CLINICAL TRIAL

Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).

A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)

CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

177. TORIPALIMAB COMBINATION WITH CHEMOTHERAPY AND SUBSEQUENT RADIATION IN PATIENTS WITH STAGE IV ESOPHAGEAL CARCINOMA，A PROSPECTIVE PHASE II STUDY (TR-EAT TRIAL)